Clinical Trials Update: June 5, 2006
Eczema (Atopic Dermatitis - Pediatric) Rheumatoid Arthritis Lupus
(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:
Eczema (Atopic Dermatitis - Pediatric)
This study will investigate if the drug pimecrolimus is safe and effective in combination with a topical corticosteroid among children with severe atopic dermatitis (eczema). Volunteers between ages 2 and 17 who have a doctor's diagnosis of atopic dermatitis covering 5 percent or more of the body not including the face may be eligible. Additional criteria apply.
Research sites are located across the United States.
This study will evaluate the safety and efficacy of intravenous fontolizumab to treat active rheumatoid arthritis. Candidates must be at least 18 years old diagnosed with rheumatoid arthritis functional class I, II, or III for at least six months, and have at least six swollen joints and six tender, painful joints. Candidates also must have been on a stable rheumatoid arthritis treatment for at least 30 days.
Research sites are located around the world.
This trial for people with lupus nephritis (LN) will evaluate an investigational drug's ability to control and maintain systemic lupus erythematosus (SLE). Volunteers must be 12 to 75, be diagnosed with SLE by a medical doctor, and have had a kidney biopsy in the last six months confirming LN. Participants will receive study medical exam, study medication at no cost, and travel reimbursement.
The research site is in Clarksville, Tenn.
Copyright 2006 CenterWatch. All rights reserved.